Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

INSM - Insmed Inc


IEX Last Trade
76.45
0.120   0.157%

Share volume: 1,721,936
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$76.33
0.12
0.16%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
38%
Profitability 41%
Dept financing 25%
Liquidity 66%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
-3.01%
1 Month
4.88%
3 Months
34.20%
6 Months
172.81%
1 Year
246.33%
2 Year
220.09%
Key data
Stock price
$76.45
P/E Ratio 
-16.37
DAY RANGE
N/A - N/A
EPS 
-$5.43
52 WEEK RANGE
$21.92 - $80.53
52 WEEK CHANGE
$2.38
MARKET CAP 
13.141 B
YIELD 
N/A
SHARES OUTSTANDING 
171.849 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,398,593
AVERAGE 30 VOLUME 
$2,217,516
Company detail
CEO: William Lewis
Region: US
Website: http://www.insmed.com/
Employees: 778
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.

Recent news